8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Oct 8, 2008)

Filed October 8, 2008For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report on October 8, 2008, primarily to disclose their response to Eli Lilly and Company's announcement to acquire ImClone Systems Incorporated for $70 per share. This event is significant as ImClone Systems was a key partner for BMY, particularly regarding the blockbuster cancer drug Erbitux. The company's press release, attached as an exhibit, likely addresses the strategic implications of this acquisition for BMY, its existing collaboration with ImClone, and potential impacts on the future of Erbitux. Investors should pay close attention to BMY's official commentary on the Eli Lilly/ImClone deal. This filing indicates BMY's proactive engagement with this market-moving news. The focus will be on how BMY intends to navigate the altered landscape, potentially including securing its rights related to Erbitux or exploring alternative strategies to mitigate any adverse effects on its product pipeline and revenue streams.

Key Highlights

  • 1BMY issued a press release on October 6, 2008, in response to Eli Lilly's announcement to acquire ImClone Systems.
  • 2Eli Lilly's acquisition offer for ImClone was $70 per share.
  • 3ImClone Systems is a significant partner for BMY, particularly concerning the drug Erbitux.
  • 4The 8-K filing incorporates BMY's press release by reference as Exhibit 99.1.
  • 5This filing signals BMY's awareness and commentary on a major industry development impacting a key partnership.

Frequently Asked Questions

The main reason for this 8-K filing is to disclose Bristol-Myers Squibb's (BMY) press release responding to Eli Lilly and Company's announcement to acquire ImClone Systems Incorporated for $70 per share.

ImClone Systems is a significant partner for Bristol-Myers Squibb, notably in the development and commercialization of the cancer drug Erbitux.

The press release, dated October 6, 2008, provides Bristol-Myers Squibb's commentary and response to Eli Lilly's proposed acquisition of ImClone Systems. Specific details on BMY's strategic position or concerns regarding Erbitux would be within this document.

Eli Lilly's acquisition of ImClone could potentially impact BMY's collaboration and future prospects related to Erbitux, depending on the terms of the existing partnership and BMY's contractual rights. BMY's press release likely addresses these implications.